HUMACYTE ($HUMA) is expected to release its quarterly earnings data on Friday, March 21st after market close, per Finnhub. Analysts are expecting revenue of $218,575 and earnings of -$0.26 per share.
You can see Quiver Quantitative's $HUMA stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
HUMACYTE Insider Trading Activity
HUMACYTE insiders have traded $HUMA stock on the open market 9 times in the past 6 months. Of those trades, 3 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $HUMA stock by insiders over the last 6 months:
- BRADY W DOUGAN has made 1 purchase buying 1,797 shares for an estimated $7,978 and 3 sales selling 1,500,000 shares for an estimated $6,606,799.
- LAURA E NIKLASON (President, CEO and Director) has made 1 purchase buying 1,797 shares for an estimated $7,978 and 3 sales selling 1,500,000 shares for an estimated $6,606,799.
- MICHAEL T. CONSTANTINO purchased 4,600 shares for an estimated $20,181
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
HUMACYTE Hedge Fund Activity
We have seen 88 institutional investors add shares of HUMACYTE stock to their portfolio, and 77 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WOODLINE PARTNERS LP added 2,000,268 shares (+235.7%) to their portfolio in Q4 2024, for an estimated $10,101,353
- CENTERBOOK PARTNERS LP added 1,279,839 shares (+inf%) to their portfolio in Q4 2024, for an estimated $6,463,186
- UBS GROUP AG added 937,539 shares (+509.5%) to their portfolio in Q4 2024, for an estimated $4,734,571
- BREVAN HOWARD CAPITAL MANAGEMENT LP added 846,070 shares (+2795.1%) to their portfolio in Q4 2024, for an estimated $4,272,653
- VOLORIDGE INVESTMENT MANAGEMENT, LLC removed 760,738 shares (-60.4%) from their portfolio in Q4 2024, for an estimated $3,841,726
- RENAISSANCE TECHNOLOGIES LLC removed 600,300 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $3,265,632
- VANGUARD GROUP INC added 543,995 shares (+10.8%) to their portfolio in Q4 2024, for an estimated $2,747,174
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
HUMACYTE Analyst Ratings
Wall Street analysts have issued reports on $HUMA in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- H.C. Wainwright issued a "Buy" rating on 11/05/2024
- Cowen & Co. issued a "Buy" rating on 10/18/2024
- BTIG issued a "Buy" rating on 10/18/2024
To track analyst ratings and price targets for HUMACYTE, check out Quiver Quantitative's $HUMA forecast page.
HUMACYTE Price Targets
Multiple analysts have issued price targets for $HUMA recently. We have seen 2 analysts offer price targets for $HUMA in the last 6 months, with a median target of $8.0.
Here are some recent targets:
- Matt O'Brien from Piper Sandler set a target price of $6.0 on 10/18/2024
- Ryan Zimmerman from BTIG set a target price of $10.0 on 10/18/2024
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
